INNOVAHEART WORKSHOP
InnovaHeart is a joint European workshop on the digital heart for a future where personalised cardiac care and healthcare innovations accelerate thanks to in-silicotrials & computational cardiology.
Bordeaux, France, 22 March 2023

The European Commission ambitions to develop an integrated human digital twin in Europe, as well as to create a diverse ecosystem in modelling and simulation approaches with a coherent roadmap. Cardiovascular diseases are identified as one strategic use case of interest for clinical trials supported by digital twinning technologies.

 

Within this framework, a one day-workshop on the Digital Heart, initiated by the EU funded project SimCardioTest, and co-organised by the EU-funded Research and Innovation Actions SIMCor, SimInSitu, the Coordination and Support Action EDITH and the EIT Health project inEurHeart will gather the European scientific community, start-ups, SMEs and industrial companies working on the digital heart, on the 22nd of March in Bordeaux.  

 

This one-day workshop is a combination of lectures, roundtables and live demonstrations, with opportunities for knowledge exchange and discussion on state of the art, exploitation and regulatory approval perspectives, contributing to the creation of an e-health ecosystem dedicated to the heart well-being and cardiovascular diseases.

INNOVAHEART WK_22MARCH_PROGRAMME_AT_A_GLANCE 

AGENDA

The participation to this workshop is open to all, cardiologists, regulatory bodies, engineers, scientists from academia, SMEs and industries with registration fees.

*This workshop will be recorded. In accordance with the provisions relating to image rights, by registering, you authorise the recording of your image (photograph and video) and your voice, to be used and disseminated within the framework of any events or to schools, as well as in any communication linked to this event, without any territorial limitation, and without this conferring any remuneration, right or advantage whatsoever. These images will not be used for commercial purposes, and your dignity will be respected. An informed consent will be signed on site.

PARTICIPANTS

Oganisations expressing their interest*

*regularly updated list

  • Academia: Inria, IHU Liryc, INSERM, Univ. Bordeaux, UniversiTat Pompeu Fabra, Universitat Politècnica de València, Simula Research Laboratory, University College of London, Technical University Eindhoven, Istanbul Medipol University
  • Hospitals: Bordeaux Hospital University,  Charité Universitätsmedizin Berlin
  • SMEs/spinoff: ExactCure, InSilicoTrials, inHeart medical, Noctua care, Bitsbeat, ELEM Biotech SL, VOISIN CONSULTING LIFE SCIENCES
  • Industries: Microport, Dassault System,
  • Non-profit organisations: Avicenna Alliance, IT’IS Foundation, Virtual Physiological Human Institute,
  • Regional organisations: ALLIS-NA, TIC SANTE,
Identified Organisations
  • IRCCS Med. Institute for Transplantation and Advanced Specialized Therapies (ISMETT), European Clinical Research Infrastructure Network (ECRIN) …
  •  Cardiologs, Implicity, Medrik-dynamic, Novadiscovery, Nurea…
  • Abbott, ANSYS, Biosense Webster, Biotronik, Boston Scientific, General Electric, Medtronic, Microsoft, Philips Netherlands BV, Roche, Servier, Virtonomy…
  • EMA, FDA, European Society of Cardiology, EIT Health, European Commission, European taskforces ….
  • If you are interested in attending this workshop, to present a demo, or to sponsor the event, please contact us.
RATIONALE

Cardiovascular diseases are the leading cause of death worldwide, with 15 million people living with heart failure in Europe alone. Among those, the prevalence of heart failure alarmingly continues to rise. While new solutions are urgently required, it is especially difficult to discover new drugs or devices. Despite significant investments in R&D, the number of new drug approvals is not increasing and development cycles for novel devices remain lengthy due to the high costs and difficulty in commercialisation. Furthermore, the regulatory requirements for approval of novel devices are ever increasing.

  • The power of digital technology and data exchange is known to support innovation: artificial intelligence, high-performance computing, cloud computing, along with the internet of things, all of which continue to impact our everyday lives. Our health data is no exception, as it can significantly contribute to enhance disease prevention, early diagnosis, and the development of personalised care strategies.
    In-silico computational approaches can be used to predict complex clinical scenarios.
  • The European Commission supports the use of digital technologies and health data in the digital transformation of health and care. Along this line, the Commission has funded, inter alia, three Horizon 2020 research and innovation actions, namely SimCardioTest, SIMCor, and SimInSitu to support the development and application of in-silico testing technologies in cardiology to sustain the development of new drugs and medical devices. Besides such projects, the Commission has recently funded, a new coordination and support action, namely EDITH, to coordinate European efforts for the creation of digital twins in healthcare. EIT Health supported by the European Commission is also funding the project inEurHeart aiming at revolutionizing catheter ablation, a procedure performed in certain cardiac pathologies.
  • With these projects, methods for testing medical devices and medicines on virtual populations are developed and made available. Those models allow to meet the rigour of regulatory demands, so that the associated risks and flaws can be addressed before substantial investments in t in clinical trials. And innovative ideas could emerge from personalized simulations. For instance, outliers within patients’ cohorts or minority groups that are not usually considered in standard clinical trials (e.g., children) can be identified. Furthermore, costs and efforts for extending the scope of existing medical devices and therapies to additional patient (sub-)groups can be reduced significantly.

 

In the recent years, new approaches to modelling and simulation have begun to provide important insights into biomedical perspectives: in-silico models are used in various clinical decision support systems and in the development and testing of medical products and devices.

  • The Virtual Human Twin (VHT) is a technological and methodological framework dedicated to the sharing of experimental observations, derivation of predictive hypotheses and their integration for a continuous improvement of our understanding of human physiology and pathology, by regarding it as a single system. VHT has been designed to enable collaborative investigations of the human body, particularly for the clinical translation of patient-specific model predictions to support clinical decision-making.

As defined by Pappalardo et al (20192), in the context of in silico medicine, the term “in-silico clinical trials“ refer to the development of patient-specific models to form virtual cohorts that enable the testing of the safety and/or efficacy of new drugs and medical devices.

  • This one-day workshop will focus on the added value that in-silico technologies can have in healthcare for several dimensions:
    – Availability of reliable mechanistic knowledge, including open-source software
    – Quality and quantity of cardiac-relevant data
    – Credibility of predictions and result standardisation
    – Health policy and regulatory frameworks.
  • Appropriate time and space will be dedicated to discussions for creating a cross-sector ecosystem, as well as for exchanging tips on methodological tools to generate virtual cohorts and specific challenges of regulatory bodies in Europe and the US for in-silico clinical trials or for accessing clinical data.

    A live survey will be organised to collect opinions of the community on challenges and solutions needed to further develop in-silico technologies for cardiac care.

    A space will also be dedicated to digital health open source platforms and software. Contact us for more information.